Lipitor vs Crestor: What to Do When One Fails

How Atorvastatin and Rosuvastatin Compare at the Molecular Level

Both drugs block HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, but their pharmacokinetic profiles differ in ways that matter clinically. Atorvastatin is metabolized by CYP3A4, making it vulnerable to interactions with common drugs including clarithromycin, cyclosporine, and some HIV antiretrovirals. Rosuvastatin bypasses CYP3A4 almost entirely and is cleared mainly by CYP2C9, which has far fewer high-risk interactions in everyday prescribing.

Bioavailability and Half-Life

Atorvastatin has a half-life of approximately 14 hours, extended by its active metabolites to roughly 20 to 30 hours of effective HMG-CoA inhibition. Rosuvastatin has a half-life of about 19 hours with no meaningful active metabolites, producing a cleaner, more predictable concentration-effect relationship. Both drugs are taken once daily, but rosuvastatin's lower hepatic extraction ratio means a larger fraction of the absorbed dose reaches systemic circulation, which partly explains its greater LDL potency per milligram. Details on statin pharmacokinetics are catalogued in the FDA prescribing information for each drug.

Dose-Equivalency Table

The 2019 ACC/AHA cholesterol guideline classifies both as high-intensity statins at their upper doses, defined as achieving >50% LDL-C reduction. Atorvastatin 40 to 80 mg and rosuvastatin 20 to 40 mg both meet that threshold. At the starting tier, atorvastatin 10 mg produces roughly 39% LDL reduction while rosuvastatin 10 mg produces roughly 46%. That 6 to 10 percentage-point gap persists across the dose range, which is the practical reason clinicians switch to rosuvastatin when atorvastatin at maximum dose still leaves a patient short of goal.

| Atorvastatin dose | Approx. LDL-C reduction | Rosuvastatin equivalent | Approx. LDL-C reduction | |---|---|---|---| | 10 mg | ~39% | 5 to 10 mg | ~43 to 46% | | 20 mg | ~43% | 10 mg | ~46% | | 40 mg | ~49% | 20 mg | ~52% | | 80 mg | ~55% | 40 mg | ~60 to 63% |

The Evidence Behind Each Drug

ASCOT-LLA: Atorvastatin's Landmark Trial

The Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm (ASCOT-LLA) enrolled 10,305 hypertensive patients with total cholesterol <6.5 mmol/L and no prior coronary disease. Atorvastatin 10 mg daily reduced the primary endpoint of non-fatal MI plus fatal CHD by 36% vs placebo (HR 0.64, 95% CI 0.50 to 0.83, P<0.001) over a median follow-up of 3.3 years. The trial was stopped early due to efficacy. Mean LDL-C fell from 3.4 mmol/L to 2.3 mmol/L in the treatment arm, a 32% reduction from a low baseline. ASCOT-LLA established that even modest LDL reduction with a low atorvastatin dose produces meaningful cardiovascular benefit in primary prevention.

JUPITER: Rosuvastatin's Landmark Trial

The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) randomized 17,802 apparently healthy adults with LDL-C <3.4 mmol/L but elevated high-sensitivity CRP (>2 mg/L). Rosuvastatin 20 mg daily reduced the composite of MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death by 44% vs placebo (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) over a median of 1.9 years. LDL-C fell by 50% and hsCRP by 37%. JUPITER also demonstrated a 20% reduction in all-cause mortality, a finding that has been cited in support of broader statin use in primary prevention.

What the Head-to-Head Data Show

No single large outcomes trial has directly compared cardiovascular mortality between atorvastatin and rosuvastatin. A 2016 network meta-analysis published in the European Heart Journal synthesized 185,000 patients across statin trials and found rosuvastatin produced the greatest absolute LDL-C reduction at maximum approved doses, though all high-intensity statins showed similar relative cardiovascular risk reduction per unit of LDL lowering. The practical implication: if atorvastatin 80 mg leaves LDL-C above goal, switching to rosuvastatin 40 mg may provide an additional 5 to 10 percentage points of LDL reduction without adding a second drug.

Defining "Failure": Three Distinct Scenarios

Statin failure is not a single event. Clinicians should separate three scenarios because each has a different management path.

Scenario 1: Inadequate LDL-C Response

A patient on atorvastatin 80 mg for 12 weeks whose LDL-C remains above the guideline-recommended target has experienced inadequate lipid response. The 2022 ACC Expert Consensus Decision Pathway defines very high-risk patients as those requiring LDL-C <1.8 mmol/L (70 mg/dL) or at least a 50% reduction from baseline. If atorvastatin at maximum dose does not get there, the first step is confirming adherence and ruling out secondary hyperlipidemia (hypothyroidism, nephrotic syndrome, uncontrolled diabetes). After that, switching to rosuvastatin 40 mg or adding ezetimibe 10 mg are equally reasonable options, with a combined rosuvastatin plus ezetimibe regimen capable of achieving 60 to 70% LDL-C reduction from baseline.

Scenario 2: Statin-Associated Muscle Symptoms

Statin-associated muscle symptoms (SAMS) affect an estimated 5 to 10% of patients in real-world practice, though randomized trial data suggest the true pharmacological rate is closer to 1 to 3% above placebo after nocebo correction. Atorvastatin and rosuvastatin carry similar myopathy risk at equipotent doses, but because rosuvastatin achieves equivalent LDL reduction at a lower dose by mass (e.g., rosuvastatin 20 mg vs atorvastatin 40 mg), switching may reduce absolute muscle exposure. The standard clinical approach when SAMS occur on atorvastatin is to hold the drug for two to four weeks, confirm that symptoms resolve, then rechallenge with rosuvastatin at a lower tier dose (start at 5 or 10 mg and titrate). If rosuvastatin at any dose also causes SAMS, every-other-day rosuvastatin 5 mg or switching to a non-statin lipid-lowering agent becomes necessary.

Scenario 3: Drug Interaction Forcing a Switch

Atorvastatin's CYP3A4 dependence creates clinically significant interactions. Cyclosporine, gemfibrozil, and some azole antifungals can raise atorvastatin plasma concentrations three to tenfold, increasing myopathy risk. In transplant patients on cyclosporine, for example, the FDA label for atorvastatin caps the dose at 10 mg due to this interaction. Rosuvastatin, with its minimal CYP3A4 involvement, is often the preferred switch in these cases, though its dose is also capped at 5 mg in cyclosporine recipients due to transport interactions via OATP1B1.

Step-by-Step Switching Protocol

When a clinician and patient agree that atorvastatin is no longer the right choice, the following sequence minimizes LDL gap time and side-effect carryover.

Step 1: Document the Reason for Switching

Record whether the switch is for efficacy, tolerability, or drug interaction. This determines the starting rosuvastatin dose. For efficacy switches, start at a dose expected to match or exceed the LDL reduction of the prior atorvastatin dose. For SAMS switches, start one or two tiers lower than the pharmacologically equivalent dose.

Step 2: Calculate the Equivalent Starting Dose

Using the equivalency table above, a patient on atorvastatin 40 mg who was tolerating it but not at LDL goal would start rosuvastatin at 20 mg. A patient switching for SAMS from atorvastatin 20 mg would start rosuvastatin at 5 or 10 mg and titrate every six to eight weeks.

Step 3: Recheck Lipids and CK at Six to Eight Weeks

A fasting lipid panel at six to eight weeks confirms whether the new dose achieves target LDL-C. Creatine kinase (CK) measurement is only necessary if the patient reports new muscle symptoms; routine CK monitoring in asymptomatic patients is not recommended by the 2019 ACC/AHA guideline.

Step 4: Add Ezetimibe If Still Off Target

If rosuvastatin 40 mg does not achieve LDL-C <1.8 mmol/L in a very high-risk patient, adding ezetimibe 10 mg is the next evidence-based step. The IMPROVE-IT trial (N=18,144) showed ezetimibe added to simvastatin 40 mg reduced the composite CV endpoint by 6.4% relative risk reduction (34.7% vs 32.7%, P=0.016) over seven years, confirming that LDL lowering below statin levels translates into additional clinical benefit.

Step 5: Consider PCSK9 Inhibition for Residual Risk

For patients at very high cardiovascular risk who remain above LDL target on maximum tolerated statin plus ezetimibe, PCSK9 inhibitors (evolocumab or alirocumab) reduce LDL-C by an additional 50 to 60% on top of background therapy. The FOURIER trial (N=27,564) showed evolocumab reduced the composite primary endpoint by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) over a median 2.2 years in patients already on optimized statin therapy.

Safety Profile Comparison

Liver Enzyme Elevations

Clinically meaningful elevations in liver transaminases (above three times the upper limit of normal) occur in fewer than 1% of patients on either atorvastatin or rosuvastatin at standard doses. The FDA removed the requirement for routine liver function monitoring in 2012 for all statins, citing that serious hepatotoxicity is rare and unpredictable, making routine testing uninformative. Baseline liver function testing before starting a statin remains reasonable practice.

New-Onset Diabetes

Statin therapy as a class carries a small but real risk of new-onset type 2 diabetes. A meta-analysis of 13 statin trials (N=91,140) found one extra case of diabetes per 255 patients treated over four years. Rosuvastatin has been associated with a modestly higher signal in some analyses, though absolute risk differences between atorvastatin and rosuvastatin remain small and are far outweighed by cardiovascular benefits in high-risk populations.

Renal Considerations

Rosuvastatin is predominantly renally excreted. In patients with severe chronic kidney disease (eGFR <30 mL/min/1.73m2), the rosuvastatin dose should not exceed 10 mg. Atorvastatin, being hepatically cleared, does not require dose adjustment in renal impairment, which makes it preferred in advanced CKD outside of dialysis. The SHARP trial (N=9,438) confirmed that simvastatin plus ezetimibe reduces major atherosclerotic events in CKD patients, reinforcing that statin therapy remains worthwhile in this population despite renal clearance adjustments.

Special Populations

Elderly Patients

Adults over 75 years without established ASCVD may see a smaller net benefit from statin initiation, but those with established coronary disease or prior stroke should continue high-intensity statin therapy regardless of age. Both atorvastatin and rosuvastatin are acceptable; rosuvastatin's lower CYP3A4 involvement reduces polypharmacy interaction risk, which is relevant given the high pill burden typical in older adults.

Women and Hormonal Therapy

Women on oral estrogen-containing hormone therapy may have modestly altered statin metabolism due to CYP3A4 induction, which can slightly reduce effective atorvastatin exposure. Transdermal estrogen does not carry this interaction. Women switching from oral to transdermal HRT while on atorvastatin should have a lipid recheck at eight weeks to confirm LDL-C control has been maintained.

Familial Hypercholesterolemia

Patients with heterozygous familial hypercholesterolemia (HeFH) typically require high-intensity statin therapy from the time of diagnosis. Maximum-dose rosuvastatin 40 mg, often combined with ezetimibe 10 mg, is a standard first-line regimen per NICE guideline CG71. Atorvastatin 80 mg is an equally acceptable alternative, but many FH specialists prefer rosuvastatin 40 mg due to its marginally greater LDL potency at the maximum dose tier.

What Patients Ask About Generics and Cost

Both drugs are off patent and available as low-cost generics. Generic atorvastatin is among the least expensive statins available, often priced below $10 per month at major pharmacy chains. Generic rosuvastatin became available in the United States in 2016 and is now similarly priced. Brand-name Crestor and Lipitor cost substantially more. Cost should not drive a clinician to keep a patient on an inadequate dose of atorvastatin when rosuvastatin might achieve target LDL-C; the ACC/AHA guideline explicitly states that generic availability should support, not limit, guideline-directed therapy.

The HealthRX Clinical Decision Summary

As the ACC/AHA 2019 cholesterol guideline states directly: "For patients with clinical ASCVD, high-intensity statin therapy should be initiated or continued with the aim of achieving at least a 50% reduction in LDL-C." When atorvastatin at 80 mg does not meet that threshold, switching to rosuvastatin 40 mg is a pharmacologically sound and well-supported maneuver.

The decision tree is short. Atorvastatin fails for one of three reasons: the LDL target is not met at maximum dose, muscle symptoms develop, or a drug interaction forces a dose ceiling. Each failure mode has a defined response. Rosuvastatin resolves the first two scenarios in most patients; it may also help the third, though the cyclosporine dose cap applies to both drugs. Adding ezetimibe or a PCSK9 inhibitor addresses persistent residual LDL elevation after statin optimization.

The clinical bottom line: if atorvastatin 80 mg leaves your LDL-C above 70 mg/dL and your cardiovascular risk is high, rosuvastatin 40 mg with or without ezetimibe 10 mg is the next prescribed step, not watchful waiting.